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Abstract: Adherence to highly active antiretroviral therapy (HAART) medication regimens 
is vital to maintaining suppression of human immunodeficiency virus (HIV), but persons 
with HIV face many challenges to adhering consistently to HIV medication regimens. This is 
particularly true for persons who live in geographically-isolated areas or who have significant 
levels of cognitive compromise. A videophone-based version of Reynolds’ HAART CARE (HC) 
telephone intervention for medication adherence was pilot-tested with 23 persons living with 
HIV residing in both urban and non-urban communities. The purpose of the pilot study was to 
evaluate the feasibility and acceptance of an adherence improvement intervention administered 
via videophones. Furthermore, the feasibility and acceptability of conducting HIV pill counts 
through videophones were assessed. The videophone version of HC produced significant 
increases in self-reported rates of medication adherence and was generally well-received by 
interventionists and participants. Pill counts conducted via videophone were also well-accepted 
by participants. Self-reported adherence levels were higher than videophone-based pill count 
adherence levels. Challenges to the use of videophones included the requirement that only analog 
landlines be used, poor quality of video and audio transmissions, and high cost for equipment. 
Methods to overcome these challenges are discussed.
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Introduction
HIV medication adherence interventions
Adherence to highly active antiretroviral therapy (HAART) is vital to maintaining the 
suppression of human immunodeficiency virus (HIV). Initially, adherence rates of 
95% or greater were recommended to promote beneficial clinical outcomes.1 However, 
recent studies suggest that the relationship between HIV medication adherence and viral 
suppression is more complex than originally presumed.2–6 For example, Bangsberg3 
found that a mean adherence rate as low as 54% might still result in HIV viral 
suppression if a patient was taking a “potent” HIV medication regimen. Despite the 
complex relationship that characterizes HIV medication adherence and viral suppression, 
Bangsberg and colleagues recommend that practitioners encourage their HIV-infected 
patients on HAART to strive for 100% adherence.3 Recommending dissimilar rates 
for different regimens might lead to confusion among many patients.
Many HIV medication adherence interventions have been tested since the 
introduction of antiretroviral therapies. Most adherence-related interventions have 
been conducted using an “in-person” format, either in clinics (one-on-one or in small 
groups) or in a person’s home.7–14 This approach may not be feasible for persons with HIV/AIDS - Research and Palliative Care 2009:1 24
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HIV who cannot or will not readily attend clinics or who 
live in rural areas.
To overcome these barriers, some adherence interven-
tions, such as Reynolds’ HAART Care (HC),15,16 have been 
conducted via telephone. Others have examined the utility 
of a web-based HIV medication adherence intervention – as 
part of a comprehensive virtual support system for persons 
living with HIV .17
In the current study, it was conjectured that an intervention 
such as HC delivered via analog videophones would create 
an “in-person” adherence intervention that could reach 
HIV-infected persons in their homes, even those living in 
rural areas.
Analog videophones were chosen for testing in the current 
study because they can be used in households with “plain 
old telephone service” (POTS) – that is, analog videophones 
do not require high speed internet access. Other televideo 
services, such as web-based videoconferencing services 
and broadband videophones, do require high speed internet 
access. When this study commenced in 2007, approximately 
47% of Americans had high speed internet at home. However, 
only 28% of persons with household incomes under $20,000 
per year had high speed internet access during this same time 
period.18 This was an important consideration for the current 
study, because many HIV positive individuals have lower 
household income levels.19
Methods of monitoring HIV 
medication adherence
Many assessment methodologies have been used to 
measure medication adherence in HIV and non-HIV-related 
research.
Self-reported medication adherence
Self-reported medication adherence is the least expensive and 
most logistically feasible method. Self-reported adherence is 
typically collected in an interview format, either in person 
or via telephone, although some researchers have collected 
self-reported adherence via online questionnaires.20 While 
self-reports are inexpensive and logistically practical, 
participants often over-report medication adherence in this 
method.20,21 In addition, self-reported medication adherence 
may not be well-suited for persons with memory problems or 
other cognitive deficits, which often are seen in persons with 
HIV .22 In fact, while some of the medical problems associated 
with HIV/AIDS have decreased over time, psychological 
and neurocognitive disorders produced by HIV/AIDS have 
remained problematic since the emergence of the disease.17 
For example, in a study of 141 HIV positive individuals, 
a 39%–41% incidence of cognitive deficits was found, as 
defined by -2.0 standard deviations on two or more neuro-
psychological measures.23 It should be noted that this study 
of 141 HIV positive individuals excluded persons who were 
already diagnosed with AIDS dementia complex (ADC). The 
prevalence of ADC and/or cognitive deficits in persons living 
with HIV is an important factor to consider when developing 
HIV adherence interventions.
Refill dates and quantity of pills dispensed  
from pharmacies
Refill dates and quantity of pills dispensed from pharmacies 
have also been used to assess HIV adherence rates.24 
However, this approach cannot be used if a participant is 
enrolled in an automatic refill program and assumes that 
pills are actually taken prior to receiving a refill. It is not 
uncommon for participants to set aside pills they did not take 
or throw them away to conceal the fact that they did not take 
their pills as prescribed.
Medication event monitoring system© (mems)
The Medication Event Monitoring System© (MEMS) is a 
common measure of medication adherence in HIV adherence 
research.20 In the MEMS approach, a special cap is placed 
on top of a standard pill bottle, and it electronically records 
when the bottle has been opened. MEMS provide researchers 
with an excellent source of objective adherence data. 
However, this technology is very expensive and assumes 
that medications are taken as prescribed whenever when a 
pill cap is opened.
Unannounced in-person pill counts
Unannounced in-person pill counts are increasingly thought 
to be one of the most valid and reliable methods of HIV 
pill counts.25 However, this method is expensive and many 
participants deny assessors permission to enter into their 
homes to conduct pill counts. Unannounced in-person pill 
counts may be best suited for areas of high population density, 
given the logistical challenges of procuring such pill counts 
in low population density areas.
Telephone-based pill counts
Kalichman and colleagues have also tested the use of 
telephone-based pill counts.26 Compared to in-person 
pill counts, telephone-based pill counts are more cost 
effective and are more feasible for HIV-infected persons in 
geographically-isolated areas. Ultimately, however, there 
is no way to verify visually the pill counts in this method. HIV/AIDS - Research and Palliative Care 2009:1 25
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It is plausible that videophones could be used to conduct 
pill counts in persons’ homes, thus providing a “visual 
verification” of the pill counts.
Project ASPIRe
This report describes the “formative phase” of an ongoing 
study called Project ASPIRE (Adherence Spaced Retrieval 
Intervention with Remote Enhancement), funded by the 
National Institute of Mental Health (Grant #R34 MH085246, 
C. Camp, PI). The formative phase of the study tested the 
feasibility and acceptability of delivering a one-on-one 
HIV medication adherence intervention via videophone to 
HIV-infected persons in urban and nonurban areas. It targeted 
persons both with and without cognitive impairment (the 
definition of “cognitive impairment” for the purposes of 
this study is provided below). A secondary aim of Project 
ASPIRE was to develop protocols for conducting pill counts 
via videophone and to assess the feasibility and acceptability 
of videophone-based pill counts.
Methods
Participants
Participants were recruited through AIDS service organizations 
in urban, rural, and suburban communities, primarily in the 
Greater New York City Area (urban) and Ohio (nonurban). 
Participants were compensated up to US$200 for their 
complete participation. All recruitment procedures and 
materials used in this study were approved by two Institutional 
Review Boards (IRB) – the Menorah Park IRB in Beachwood, 
Ohio and the Innovative Designs in Environments for an 
Aging Society (IDEAS) IRB in Kirtland, Ohio.
Participants were divided into two groups based on 
the size of the community in which they lived. “Urban” 
communities were those with a population of at least 100,000, 
and “nonurban” communities were suburban and rural towns 
with populations of less than 100,000 residents.
Study inclusion criteria were: (1) living with HIV 
infection or acquired immunodeficiency syndrome (AIDS); 
(2) being on HAART; (3) aged 18 years or older; (4) self-
reported rates of medication adherence of 75% or less over 
the past four days or self-reported “chronic problems” with 
adherence at the screening interview; and (5) having access 
to an analog telephone line.
In addition, at least 50% of participants were expected to 
evince cognitive impairment (actual percentages are shown 
below). Two cognitive assessments, the Telephone Adaptation 
of the Modified Mini-Mental State Exam (T3MS)27,28 and 
the Verbal Fluency Test (FAS),29,30 were administered to 
participants via telephone. For the T3MS, a conservative 
cutoff score of 88 was used to identify participants as 
being impaired if they had completed nine or more years 
of education, while a score of 79 indicated impairment for 
persons with less than nine years of education.28,31 FAS scores 
that were more than one standard deviation (SD) below the 
norm for each particular group were considered as evidence 
of cognitive impairment.
Procedures
Because the formative phase of Project ASPIRE was to 
test the acceptability and feasibility of delivering the HC 
intervention via videophone, all participants received the HC 
intervention. Upon enrollment in the study, each participant 
was sent a videophone (see Figure 1) and a “pill counting 
tray” (see Figure 2). Participants also received easy-to-read, 
picture-based instructions.
Intervention
The intervention tested in the formative phase of Project 
ASPIRE is an adapted version of Nancy Reynolds’ HC 
intervention.32 This individualized adherence intervention is 
guided by self-regulation theory. According to this theory and 
supporting theoretical and empirical work,33 people attempt 
to understand their illness (in this case, HIV) by developing 
a working model or of the disease (in this case, an “HIV 
representation”): its causes, effects, duration, and treatment. 
HC suggests that there are many barriers to HIV medication 
Figure 1 Videophone used in the study.HIV/AIDS - Research and Palliative Care 2009:1 26
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adherence, such as a desire to avoid negative side effects, lack 
of social support, depression, misconceptions of the disease, 
poor understanding of the effects of treatment on the disease, 
stigma, stress, and cognitive limitations, such as forgetting 
to take one’s medications. The HC intervention addresses 
each of these possible barriers and attempts to intervene 
upon factors that contribute to adherence-incompatible 
perceptions.
In Reynolds’ multicenter AIDS Clinical Trial Group 
(ACTG) 731, the HC intervention was delivered via regular 
telephone. Intervention sessions occurred once per week for 
12 weeks and then once every other week for four weeks (for 
a total of 14 sessions). The mean length of each session in 
Reynolds’ study was eight minutes.8
As modified for Project ASPIRE, the HC protocol asked 
participants to take part in eight intervention sessions twice 
per week for four weeks. Each session was expected to be 
approximately 30 minutes in duration. These changes enabled 
us to integrate a memory intervention into the HC protocol, 
a major focus of the next phase of the project.
Assessing medication adherence
Participants were assessed for medication adherence at 
baseline, at the midpoint of treatment, and at follow-up intervals 
of one-week and one-, two-, and three-months following 
treatment, using both self-report and videophone-based pill 
counts (VBPCs).
Videophone-based pill counts (VBPCs)
Because some participants had cognitive impairments, the 
pill counting procedure was simplified by selecting a single 
“anchor” HAART medication (ie, the medication with the 
most complex regimen) to be assessed during the study. 
Detailed descriptions of the specifics of conducting VBPCs 
and the method by which to define “anchor” medications are 
available from the authors upon request. The information 
gathered during each VBPC enabled researchers to calculate 
each participant’s adherence rate. See Table 1 for the formulae 
used to calculate adherence rates.
Follow-up interviews
Follow-up interviews were conducted after the intervention 
phase of the study at one-week and one-, two-, and 
three-month intervals. In addition to obtaining adherence 
estimates, participants provided data on reasons for failing to 
adhere to medication regimens, such as forgetting, not having 
their medicines with them while traveling, worries regarding 
side effects, and stigma/confidentiality concerns. Participants 
also rated their satisfaction with social support in general, and 
the extent to which family members and/or friends facilitated 
their adherence efforts. At the one-week and three-month 
follow-up interviews, participants also provided information 
about the acceptability of the videophone.
Results
Thirty-three participants were eligible to take part in the 
intervention phase of the study; 23 participants (70%) 
completed at least five of the eight intervention sessions 
and all follow-up interviews. Data presented are from these 
23 participants (12 female, 11 male, Mage = 47.95 years, age 
range: 28–59 years). Seventy percent of participants had 
been living with HIV/AIDS for more than 10 years. The 
urban sample (n = 14) had seven female participants, with 
a mean age of 50 years (age range: 38–59 years). The “non-
urban” sample (n = 9) had five female participants, with a 
mean age of 45 years (age range: 28–54 years). See Table 2 
Figure 2 Pill counting tray used for videophone-based pill counts.HIV/AIDS - Research and Palliative Care 2009:1 27
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for demographics and Table 3 for scores on tests of cognitive 
assessment at baseline.
Feasibility of delivering intervention  
via videophones
Comparisons with Reynolds’ outcomes
Reynolds and colleagues8 reported that 70% of all scheduled 
phone calls were completed successfully in their multicenter 
randomized, controlled trial. In the current study, 80.3% of all 
scheduled intervention videophone calls were completed as 
scheduled. The mean session length of these completed sessions 
was 23 minutes. Reynolds’ sample had not yet started HAART 
before receiving HC or a control condition, but self-reported 
levels of compliance with recently prescribed non-HAART 
medications in Reynolds’ sample were high (M = 97% treat-
ment; 98% controls) before starting a HAART regimen. At 
four and 16 weeks after the start of treatment in Reynolds’ 
study, mean adherence rates for HAART regimens were 
reported to be 98% for the treatment group and 97% for the 
control group. In the current sample, mean HAART adherence 
was self-reported to be 63% before HC, 91% at mid-treat-
ment, and 92% at 16 weeks after initiation of HC. Depen-
dent t-tests revealed a significant increase in self-reported 
adherence from baseline to mid-treatment (P  0.01) and 
from pre-treatment to 16-week follow-up (P  0.01), with 
no difference in adherence rates between mid-treatment and 
16-week follow up (suggesting that the increase in adherence 
was maintained from mid-treatment to 16-week follow up). 
Urban and nonurban participants reported similar levels of 
adherence. There were no significant correlations between 
adherence and the FAS (r = 0.12, P  0.60) and adherence 
and the T3MS (r = 0.39, P  0.08).
Reynolds and colleagues reported a 67% satisfaction 
rate with general social support at baseline. Post-treatment 
social support was not reported in the Reynolds’ study. 
In the current study, 89% of participants stated that they 
were satisfied with their general social support at baseline 
and at the three-month follow up. In the current study, 57% 
of participants stated that they received at least some help 
from family or friends with their adherence efforts baseline, 
compared to 67% at the three-month follow-up. This differ-
ence was not significant (P = 0.43).
Barriers to using videophones
One barrier to conducting the HC intervention over 
videophones was finding people who had analog telephone 
lines. Many potential participants had only a cell phone, while 
others had a digital phone service, which is incompatible with 
analog videophones. In fact, approximately 15% of persons 
interested in the study could not participate because they did 
not have analog telephone landlines.
Some participants and interventionists felt that the quality 
of the video signal was poor and detrimentally affected the 
quality of intervention sessions. Another problem to the use 
of videophones is their prohibitive cost. Each videophone 
used in this study cost approximately $1700.
Acceptability of videophone-based 
intervention
In general, videophones were well-accepted by participants 
and interventionists, even though some people felt that the 
video and audio quality was poor. All 23 participants stated 
that they would “be willing to use a videophone again in the 
future” and that they “felt comfortable using the videophone.” 
Twenty participants (87%) stated that they found it “easy to 
use the videophone.” Seventeen participants (73.9%) said that 
they “liked the videophones.” Four out of five interventionists 
said that they would be willing to use videophones again in the 
future and that they felt comfortable using videophones.
Feasibility and acceptability of conducting 
pill counts via videophone
After a considerable amount of in-house pilot testing, the 
study team developed a videophone-based pill counting 
protocol that was efficient and well-accepted by participants. 
Most pill counts lasted 15–30 minutes. No participants 
withdrew from the study due to the burden of conducting 
pill counts. Participants with an education level as low as 
Table 1 Formulae for calculating adherence rates
Adherence rate since last pill count =  # of pills taken since last pill count ÷ # of pills should have taken since last pill count
# of pills taken since last pill count = (# of pills counted at last pill count + # of pills from refills since last pill count) – (# of pills thrown 
away + # of pills given away/sold + # of pills lost + # of pills broken + # of pills taken, but taken 
too early/late day of THIS pill count) – (# of pills counted from all locations at this pill count)
# of pills the person should have taken since  
the last pill count =
[(# of full days since last pill count) x (# of pills per day)] + (# of pills that should have been taken 
later in the day at the last pill count) + (# of pills that should have been taken earlier in the day at 
THIS pill count)HIV/AIDS - Research and Palliative Care 2009:1 28
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8–11 years, T3MS scores as low as 68, and FAS scores as low 
as -2.29 SD were able to complete successfully pill counts.
VBPC adherence data and correlations 
with self-reported adherence data
Videophone-based pill count adherence rates calculated 
after treatment were combined into a composite score for 
each participant. This composite score was required due to 
data missing for most participants at some point during post-
treatment. Videophone-based adherence rates improved from 
60% before HC to 82% at post-treatment, though this change 
was not statistically significant. There were no significant 
differences between videophone-based pill count adherence 
levels of the urban and nonurban groups.
For a subset of 17 participants, all of whom had complete 
data for all time points, self-reported adherence rates were 
not correlated with VBPC adherence rates, suggesting that 
participants may have had little insight into their actual adherence 
rates. However, self-reported adherence rates at baseline were 
correlated with self-reported post-treatment adherence rates 
(r = 0.65, P  0.01), and the two VBPC adherence rates were 
correlated with one another (r  = 0.60, P  0.05).
Discussion
As HIV infection is increasingly transformed to a chronic, 
albeit manageable, disease, cost-effective and more 
readily accessible interventions that can intervene upon 
and assess medication adherence in persons with HIV are 
urgently needed. Videophone technology appears to be an 
efficacious way by which to deliver adherence-improvement 
interventions to persons living with HIV/AIDS. In addition, 
pill counts conducted with videophones can provide more 
objective information regarding levels of adherence than 
self-report. This may be especially critical when working 
with persons who have cognitive impairment.
All of our participants, even those with evidence of 
cognitive impairment, were able to install and utilize video-
phones when we could talk them through the process over 
a regular phone line. However, we found it was necessary 
to supplement our verbal instructions with picture-based 
instructions. The participant’s ability to refer to pictures of 
items such as “telephone splitters” and “telephone jacks” was 
vital to the successful installation and use of videophones. 
Study staff found that it was important to be patient with, 
and encouraging of, participants as they attempted to install 
and operate videophones. Research staff concluded that the 
installation process was more effective if short sentences and 
simple vocabulary were used during the instructional period 
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and if they prompted participants with questions throughout 
the installation period (eg, “So, which jack is the cord plugged 
into now?”). After videophones were installed, participants 
had relatively few problems understanding the proper use 
of the videophone.
Nonetheless, future research on this topic should attempt 
to address and resolve potential difficulties associated 
with the prohibitive costs of videophones. As videophone 
technology increases in sophistication and as more areas 
of the United States receive state-of-the-science broadband 
capacity, perhaps some of these issues will be resolved.
In the meantime, the provision of inexpensive laptops 
($300–$400) and mobile broadband internet access, 
which would enable participants to use Skype or a similar 
technology, is one potential solution to address cost dilemmas 
in the immediate future. Indeed, it might even be more cost-
effective to permit participants to keep laptops provided to 
them as opposed to purchasing numerous videophones (some 
of which malfunction or are not returned after their scheduled 
use). Permitting participants to keep laptops would provide 
several benefits. It would act as an incentive to take part in the 
study (videophones had to be returned, which was an added 
expense and logistical challenge for the project), and help in 
other ways (eg, making available automatic email reminders, 
HIV education materials online, etc.) All of this could be 
achieved at a much lower cost than using current videophone 
technology. As mentioned earlier, some researchers have 
already begun to pilot test the use of a web-based HIV 
medication adherence intervention.17 Additional research 
in web-based televideo is warranted, especially given the 
encouraging preliminary results of this study.
The current study has several limitations worthy of 
comment. First, the sample was a relatively small convenience 
sample. Second, biologic data (eg, HIV viral load and CD4 
cell counts) were not collected in this study; future research 
on videophone-administered adherence interventions should 
examine results using more objective immunologic measures. 
Third, all participants were recruited through AIDS service 
organizations and, as such, had access to at least some medi-
cal and mental health care supportive services; the adherence 
needs of persons who are not connected with these types of 
supportive services may be even greater.
In spite of these limitations, this is perhaps the first 
study to show that the adherence efforts of persons living 
with HIV/AIDS can be enhanced through interventions 
delivered using videophone technology. Not only did the 
intervention show potential to improve adherence in this 
geographically-diverse group, but the videophone provided 
a more objective methodology by which to assess participant 
adherence (ie, videophone-based pill counts). The promising 
results observed in this pilot study clearly warrant additional 
research on the topic of administering adherence improvement 
interventions to persons living with HIV/AIDS through the 
rapidly evolving technology of videophone systems.
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